Time on boards
- Boards served
- 4
- Current seats
- 4
- Board service
- 13 years
- Director since
- 2023
13 years of board service in total across 4 boards, counting each seat separately. Longest: BioMarin Pharmaceutical Inc., 3 years.
BioMarin Pharmaceutical Inc.
Director
Kyntra Bio Inc.
Director
Agios Pharmaceuticals Inc.
Director
Neumora Therapeutics Inc.
Director
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
BioMarin Pharmaceutical Inc. June 2, 202698.0%
-
Neumora Therapeutics Inc. May 28, 202598.3%
-
BioMarin Pharmaceutical Inc. May 20, 202598.9%
-
Agios Pharmaceuticals Inc. June 20, 202491.3%
-
BioMarin Pharmaceutical Inc. May 21, 202494.2%
-
BioMarin Pharmaceutical Inc. May 23, 202399.4%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 18, 2026 | Agios Pharmaceuticals Inc. | Option exercise | +2,816 | — | — |
| Jun 2, 2026 | BioMarin Pharmaceutical Inc. | Grant or award | +7,490 | — | — |
| Jun 20, 2025 | Agios Pharmaceuticals Inc. | Option exercise | +2,120 | — | — |
| May 20, 2025 | BioMarin Pharmaceutical Inc. | Grant or award | +6,650 | — | — |
| Jun 13, 2024 | Agios Pharmaceuticals Inc. | Option exercise | +3,388 | — | — |
| Jun 13, 2024 | Neumora Therapeutics Inc. | Grant or award | +20,100 | — | — |
| May 21, 2024 | BioMarin Pharmaceutical Inc. | Grant or award | +4,720 | — | — |
| Jun 21, 2023 | Agios Pharmaceuticals Inc. | Option exercise | +4,975 | — | — |
| Jun 8, 2023 | Kyntra Bio Inc. | Open-market sale | −2,295 | $16.79 | $38,533 |
| Jun 8, 2023 | Kyntra Bio Inc. | Open-market sale | −6,225 | $17.68 | $110,058 |
| Jun 7, 2023 | Kyntra Bio Inc. | Grant or award | +8,289 | — | — |
| May 23, 2023 | BioMarin Pharmaceutical Inc. | Grant or award | +4,190 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.